Search

The article details a case of a Cavalier King Charles Spaniel presenting with respiratory distress, investigated through point-of-care ultrasound and blood analysis. Findings revealed severe pulmonary parenchymal disease, non-regenerative anemia, and thrombocytopenia, prompting consideration of various causes such as pulmonary edema, pneumonia, and inherited macrothrombocytopenia in the breed.

The article focuses on the development of the human lung surfactant protein that can be used for the treatment of respiratory distress syndrome in infants. Around 10% infants die annually due to the respiratory distress syndrome. According to officials of California Biotechnology Inc., the company can use the recombinant DNA technology to make surfactant proteins. James W. Schilling, a physician, believes that the disease can be treated by applying the protein directly into the lungs.

The article presents a case study of a neonate girl who had developed vomiting during treatment with citric acid/sodium citrate for anaemia and respiratory distress.

The article discusses a study published in the September 30, 2014 issue of the "New England Journal of Medicine" on 540 patients with acute respiratory distress syndrome (ARDS) secondary to sepsis, to determine benefits of use of statins for ventilator-free days or 28-day mortality.

The article informs that Research & Markets Ltd. has announced the inclusion of the business analyst Global Markets Direct's report "Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011" to their offering. The report provides an overview of the Neonatal Respiratory Distress Syndrome (NRDS) therapeutic pipeline. It also provides information on the therapeutic development for NRDS with special features on late-stage and discontinued projects.

The article offers information on the report "Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011" from Global Markets Direct. It notes that the report provides updates, trends analysis, and the therapeutic development for acute respiratory distress syndrome. Moreover, the scope of the report includes key players, reviews of products, and pipeline projects on the basis of monotherapy and combined therapeutics for acute respiratory distress syndrome.

The article discusses a prospective cohort study in 50 countries which examined admissions and subsequent care of patients with acute respiratory distress syndrome (ARDS) during 4 consecutive winter weeks in 2014 and found that standardized care is poor and mortality is high.

The article discusses research being done on the physiological effect of recombinant surfactant protein-C (rSP-C) surfactant on acute respiratory distress syndrome (ARDS). It references a study by Friedemann J. H. Taut et al, which appeared in the October 2008 issue of "Chest." Researchers assessed 28-day mortality, oxygenation, and ventilator-free days to day 28. They concluded that patients with direct ARDS may benefit most from surfactant treatment due to their lower pulmonary compliance than those with indirect lung injury.

The article discusses a study conducted in several countries which argues that the conventional ventilation method is better than the high-frequency oscillatory ventilation for patients in intensive care. Topics mentioned include the risks of death for adults suffering from a respiratory distress syndrome, their need for ventilation, and their vulnerability.

The article informs that the Queen's University in Belfast, Ireland is running a clinical trial of the drug statins for the treatment of acute respiratory distress syndrome.

This section offers healthcare news briefs. A study printed in the March 2012 issue of "European Respiratory Journal" revealed that sniff dogs were able to detect lung cancer by smelling patients' breath. A February 27, 2012 report in the "Annals of Internal Medicine" disclosed that rapid influenza diagnostic tests can help identify influenza but it cannot rule it out. The U.S. Food and Drug Administration has approved the drug Surfaxin for respiratory distress syndrome in infants.

The article offers information on a new discovery, a new drug Surfaxin used for treatment against respiratory distress syndrome by the Scripps Research Institute in La Jolla, California and information about the approval of this drug by the U.S. Food and Drug Administration is also presented.

The article traces the history of tracheotomy as a surgical intervention for respiratory distress. Dating back to the ancient times, tracheotomy was first used by Thomas Fienus in 1649, first saw print in a 1748 text by Lorenz Heister and later promoted by Armand Trousseau (1801-1867). Chovell used the procedure in a money-making scheme in 1732 while physician Alois Monti assessed the success of tracheotomy in 12,000 cases of laryngeal diphtheria. By mid-19th century, the procedure was used to treat epilepsy, tetanus and, probably, even burn cases.

Reports that the Chinese medical herb Banlangen is being used to help severe acute respiratory syndrome (SARS) patients for its abilities to activate the human immune system.

Discusses the effectiveness of the ibuprofen drug as a treatment for a blood-vessel problem which causes respiratory distress in premature infants.

Reports on the development of an implantable artificial lung as an alternative to an external respirator for acute respiratory distress. The downfall of respirators; Developments by researchers at Northwestern University; Attaching of the experimental device to pigs; The desire by researchers to make a lung that can be tested in sheep.

Reports that T. Allen Merritt of the UCSD Medical Center in San Diego, California, has established a bank for amniotic fluids. Presence of a vital lung chemical in amniotic fluid; Importance of the lung chemical for premature babies with respiratory distress syndrome.

Reports on the efficacy of perflubron in treating premature babies suffering from surfactant deficiency. Perflubron as a way to help infants suffering from severe respiratory distress syndrome; How the substance works in the lungs; The exchange of carbon dioxide for oxygen; Report from Corinne Lowe Leach and colleagues in the September 12, 1996 `New England Journal of Medicine'; Study done at the State University of New York in Buffalo, New York.

Reports on the treatment for respiratory distressed syndrome which frequently occurs among premature babies born in the U.S. Advantages of lubricating distressed lungs with delivery of oxygen and air under pressure; Reason for respiratory distressed syndrome in premature babies; Significance of treating patient with oxygen therapy.

Focuses on nitric oxide, a possible treatment for preterm babies who have respiratory distress syndrome (RDS). How nitric oxide works; Where the nitric-oxide treatment is available.